Possible scenario
Valuation Pullback
30% Chance
The market begins to question whether the rally has run too far ahead of revenue conversion. After becoming the S&P 500's top performer, Moderna is vulnerable to profit-taking and valuation discipline.
Secondary impacts
- Healthcare -0.2%
Tickers
- MRNA-6.8%
- MRK-0.4%
Portfolio impact
S&P 500-0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.